Viva Biotech Maintains 2.13 Billion Issued Shares in May 2026; 19.94 Million Repurchased Shares Await Cancellation

Bulletin Express06-03 16:25

For the month ended 31 May 2026, Viva Biotech reported no changes in its authorised or issued share capital. Authorised capital remained at 4.00 billion ordinary shares with a par value of USD 0.000025, equivalent to USD 100,000.

Issued shares (excluding treasury shares) stayed at 2.13 billion, and the company held no treasury shares at month-end. The public-float level continued to meet the Main Board’s minimum 25 % requirement.

Repurchase activity earlier in the period left 19.94 million ordinary shares pending formal cancellation as of 31 May 2026. No new shares were issued, cancelled, or transferred during the month.

Outstanding equity incentives were unchanged: 2.22 million options under Pre-IPO schemes and 13.70 million options under the Post-IPO Share Option Scheme remained unexercised, with no option grants, exercises, cancellations, or lapses recorded in May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155909592?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 16:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155909592","market":"hk","top_or_hot":-1,"title":"Viva Biotech Maintains 2.13 Billion Issued Shares in May 2026; 19.94 Million Repurchased Shares Await Cancellation","media":"Bulletin Express","content":"<p>For the month ended 31 May 2026, Viva Biotech reported no changes in its authorised or issued share capital. Authorised capital remained at 4.00 billion ordinary shares with a par value of USD 0.000025, equivalent to USD 100,000.</p>\n<p>Issued shares (excluding treasury shares) stayed at 2.13 billion, and the company held no treasury shares at month-end. The public-float level continued to meet the Main Board’s minimum 25 % requirement.</p>\n<p>Repurchase activity earlier in the period left 19.94 million ordinary shares pending formal cancellation as of 31 May 2026. No new shares were issued, cancelled, or transferred during the month.</p>\n<p>Outstanding equity incentives were unchanged: 2.22 million options under Pre-IPO schemes and 13.70 million options under the Post-IPO Share Option Scheme remained unexercised, with no option grants, exercises, cancellations, or lapses recorded in May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech Maintains 2.13 Billion Issued Shares in May 2026; 19.94 Million Repurchased Shares Await Cancellation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech Maintains 2.13 Billion Issued Shares in May 2026; 19.94 Million Repurchased Shares Await Cancellation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-03 16:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>For the month ended 31 May 2026, Viva Biotech reported no changes in its authorised or issued share capital. Authorised capital remained at 4.00 billion ordinary shares with a par value of USD 0.000025, equivalent to USD 100,000.</p>\n<p>Issued shares (excluding treasury shares) stayed at 2.13 billion, and the company held no treasury shares at month-end. The public-float level continued to meet the Main Board’s minimum 25 % requirement.</p>\n<p>Repurchase activity earlier in the period left 19.94 million ordinary shares pending formal cancellation as of 31 May 2026. No new shares were issued, cancelled, or transferred during the month.</p>\n<p>Outstanding equity incentives were unchanged: 2.22 million options under Pre-IPO schemes and 13.70 million options under the Post-IPO Share Option Scheme remained unexercised, with no option grants, exercises, cancellations, or lapses recorded in May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1155909592","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155909592","pubTimestamp":1780475102,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"For the month ended 31 May 2026, Viva Biotech reported no changes in its authorised or issued share capital. Authorised capital remained at 4.00 billion ordinary shares with a par value of USD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"维亚生物2026年5月维持21.3亿股已发行股份；1994万股回购股份等待注销","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"For the month ended 31 May 2026, Viva Biotech reported no changes in its authorised or issued share capital. Authorised capital remained at 4.00 billion ordinary shares with a par value of USD 0.000025, equivalent to USD 100,000.\nIssued shares (excluding treasury shares) stayed at 2.13 billion, and the company held no treasury shares at month-end. The public-float level continued to meet the Main Board’s minimum 25 % requirement.\nRepurchase activity earlier in the period left 19.94 million ordinary shares pending formal cancellation as of 31 May 2026. No new shares were issued, cancelled, or transferred during the month.\nOutstanding equity incentives were unchanged: 2.22 million options under Pre-IPO schemes and 13.70 million options under the Post-IPO Share Option Scheme remained unexercised, with no option grants, exercises, cancellations, or lapses recorded in May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155909592","isCrawlerRequest":true}